vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $12.5M, roughly 1.5× SOLESENCE, INC.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -0.8%, a 2.1% gap on every dollar of revenue. On growth, SOLESENCE, INC. posted the faster year-over-year revenue change (-0.7% vs -25.7%). Over the past eight quarters, SOLESENCE, INC.'s revenue compounded faster (12.5% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CTMX vs SLSN — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $12.5M |
| Net Profit | $-154.0K | $163.0K |
| Gross Margin | — | 27.5% |
| Operating Margin | -6.9% | 1.5% |
| Net Margin | -0.8% | 1.3% |
| Revenue YoY | -25.7% | -0.7% |
| Net Profit YoY | 97.6% | 129.2% |
| EPS (diluted) | — | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.5M | ||
| Q3 25 | — | $14.6M | ||
| Q2 25 | $18.7M | $20.4M | ||
| Q1 25 | $50.9M | $14.6M | ||
| Q4 24 | $38.1M | $12.6M | ||
| Q3 24 | $33.4M | $16.9M | ||
| Q2 24 | $25.1M | $13.0M | ||
| Q1 24 | $41.5M | $9.9M |
| Q4 25 | — | $163.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | $-154.0K | $2.7M | ||
| Q1 25 | $23.5M | $80.0K | ||
| Q4 24 | $18.9M | $-559.0K | ||
| Q3 24 | $5.7M | $3.0M | ||
| Q2 24 | $-6.5M | $856.0K | ||
| Q1 24 | $13.8M | $893.0K |
| Q4 25 | — | 27.5% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | 22.0% | ||
| Q3 24 | — | 36.2% | ||
| Q2 24 | — | 28.7% | ||
| Q1 24 | — | 36.3% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | — | -5.4% | ||
| Q2 25 | -6.9% | 9.4% | ||
| Q1 25 | 44.4% | 1.8% | ||
| Q4 24 | 46.4% | -1.8% | ||
| Q3 24 | 12.3% | 19.0% | ||
| Q2 24 | -33.7% | 8.0% | ||
| Q1 24 | 28.1% | 11.3% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | -7.7% | ||
| Q2 25 | -0.8% | 13.1% | ||
| Q1 25 | 46.2% | 0.5% | ||
| Q4 24 | 49.6% | -4.4% | ||
| Q3 24 | 17.2% | 18.1% | ||
| Q2 24 | -26.0% | 6.6% | ||
| Q1 24 | 33.3% | 9.0% |
| Q4 25 | — | $0.00 | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | — | $0.04 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | — | $0.04 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $17.6M |
| Total Assets | $175.1M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3M | ||
| Q3 25 | — | $429.0K | ||
| Q2 25 | $49.0M | $4.1M | ||
| Q1 25 | $47.6M | $1.8M | ||
| Q4 24 | $38.1M | $1.4M | ||
| Q3 24 | $40.6M | $2.9M | ||
| Q2 24 | $43.2M | $2.4M | ||
| Q1 24 | $36.2M | $2.0M |
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $17.2M | ||
| Q2 25 | $119.9M | $18.2M | ||
| Q1 25 | $25.0M | $15.2M | ||
| Q4 24 | $-456.0K | $14.9M | ||
| Q3 24 | $-23.5M | $15.2M | ||
| Q2 24 | $-31.2M | $11.9M | ||
| Q1 24 | $-31.7M | $5.0M |
| Q4 25 | — | $50.1M | ||
| Q3 25 | — | $54.0M | ||
| Q2 25 | $175.1M | $60.0M | ||
| Q1 25 | $98.5M | $57.0M | ||
| Q4 24 | $120.5M | $50.0M | ||
| Q3 24 | $139.0M | $48.0M | ||
| Q2 24 | $159.2M | $40.8M | ||
| Q1 24 | $184.7M | $38.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $1.8M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.8M | ||
| Q3 25 | — | $-2.5M | ||
| Q2 25 | $-15.8M | $-654.0K | ||
| Q1 25 | $-21.0M | $-7.2M | ||
| Q4 24 | $-19.9M | $2.2M | ||
| Q3 24 | $-20.7M | $4.2M | ||
| Q2 24 | $-19.5M | $-565.0K | ||
| Q1 24 | $-26.0M | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | $-404.0K | ||
| Q3 24 | $-20.7M | $2.8M | ||
| Q2 24 | $-19.6M | $-1.0M | ||
| Q1 24 | $-26.2M | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | -3.2% | ||
| Q3 24 | -62.1% | 16.6% | ||
| Q2 24 | -78.2% | -8.0% | ||
| Q1 24 | -63.1% | -39.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | 20.6% | ||
| Q3 24 | 0.1% | 8.3% | ||
| Q2 24 | 0.4% | 3.7% | ||
| Q1 24 | 0.3% | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.25× | ||
| Q1 25 | -0.89× | -90.26× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | -1.89× | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SLSN
Segment breakdown not available.
